Mitchell Kapoor Reaffirms Buy Rating for Summit Therapeutics Amid Promising Ivonescimab Trial Results
Truist Financial Maintains Summit Therapeutics(SMMT.US) With Buy Rating
Jefferies Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $31
Cantor Fitzgerald Maintains Summit Therapeutics(SMMT.US) With Buy Rating
Summit Therapeutics Analyst Ratings
Truist Financial Reaffirms Their Buy Rating on Summit Therapeutics (SMMT)
JMP Securities Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $32
Truist Financial Maintains Summit Therapeutics(SMMT.US) With Buy Rating
Truist Financial Maintains Summit Therapeutics(SMMT.US) With Buy Rating
Cantor Fitzgerald Maintains Summit Therapeutics(SMMT.US) With Buy Rating
Summit Therapeutics (SMMT) Gets a Buy From Truist Financial
Optimistic Buy Rating for Summit Therapeutics Driven by Promising HARMONi-2 Trial and Favorable Regulatory Pathway in China
Cantor Fitzgerald Maintains Summit Therapeutics(SMMT.US) With Buy Rating
Citi Upgrades Summit Therapeutics(SMMT.US) to Buy Rating, Raises Target Price to $35
Citigroup Upgrades Summit Therapeutics to Buy, Raises Price Target to $35
Cantor Fitzgerald Initiates Summit Therapeutics(SMMT.US) With Buy Rating
Summit Therapeutics Analyst Ratings
Evercore Initiates Summit Therapeutics(SMMT.US) With Buy Rating, Announces Target Price $30
Stifel Upgrades Summit Therapeutics(SMMT.US) to Buy Rating, Maintains Target Price $40
Evercore ISI Group Initiates Coverage On Summit Therapeutics With Outperform Rating, Announces Price Target of $30